 CARLSBAD, Calif. , Sept. 5, 2022 PRNewswire -- Tyra Biosciences, Inc. Nasdaq: TYRA, a precision oncology company focused on developing purpose-built therapies to overcome tumor resistance and improve outcomes for patients with cancer, today announced that the Company will be presenting preclinical data on TYRA-300 during a poster session at the European Society for Medical Oncology ESMO 2022 Congress, being held in person September 9-13, 2022 in Paris, France. 